{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:59:27Z","timestamp":1789556367100,"version":"build-2803163510"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"Importance<\/jats:title>Symptoms suggestive of coronary artery disease (CAD) often require noninvasive testing for diagnostic and prognostic evaluation.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine long-term outcomes in patients randomized to functional (stress) vs anatomic (coronary computed tomographic angiography [CTA]) initial testing.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This study is a 2025 follow-up analysis of mortality of participants in the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) randomized clinical trial, which was conducted from 2009 to 2014, using a 2024 National Death Index search. Median (IQR) follow-up duration was 10.6 (9.9-11.3) years; maximum follow-up was 12.4 years. PROMISE was conducted at 193 multispecialty outpatient sites in North America among 10\u202f003 symptomatic patients requiring testing for suspected CAD. Data analysis was conducted from August 2024 to March 2025.<\/jats:p><\/jats:sec>Intervention<\/jats:title>Participants were randomized 1:1 to initial CTA or stress testing. Testing and subsequent care were performed by sites according to usual practices.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The PROMISE trial\u2019s original primary end point was death, myocardial infarction, unstable angina hospitalization, or major procedural complication. The primary end point for extended follow-up was all-cause death, with cardiovascular (CV) death as a secondary end point.<\/jats:p><\/jats:sec>Results<\/jats:title>At enrollment, mean (SD) participant age was 61 (8) years, 5270 participants (52.7%) were women, and 8762 (87.6%) had chest pain or dyspnea. Death occurred in 1128 participants (14.4%), including 558 (14.3%) in the CTA arm and 570 (14.5%) in the stress arm (unadjusted hazard ratio [HR], 0.98; 95% CI, 0.87-1.10). There was no demonstrable difference in cardiovascular mortality, although the point estimate favored CTA (HR, 0.84; 95% CI, 0.67-1.05; adjusted HR, 0.89; 95% CI, 0.41-1.94). There were no significant interactions between all-cause death or CV death and study arm by age (&amp;lt;60 or \u226560 years) (P<\/jats:italic> value for interaction\u2009=\u2009.19), gender (P<\/jats:italic> value for interaction\u2009=\u2009.60), or race and ethnicity (P<\/jats:italic> value for interaction\u2009=\u2009.47). A CTA indicating any degree of abnormality, including mild (nonobstructive CAD), moderate, and severe findings, conferred elevated adjusted HRs of death (1.99-3.44; all P<\/jats:italic>\u2009&amp;lt;\u2009.001) compared to normal study results. Among stress testing results, only a severe abnormality was prognostically significant (HR, 1.45; 95% CI, 1.10-1.91). In landmark analyses of those alive at 90 days, there were no interactions between randomized testing and use of statins (P<\/jats:italic> value for interaction\u2009=\u2009.22), \u03b2-blockers (P<\/jats:italic> value for interaction\u2009=\u2009.76), or antiplatelet agents (P<\/jats:italic> value for interaction\u2009=\u2009.49).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In long-term follow-up of the PROMISE randomized clinical trial, initial noninvasive test selection in patients with stable symptoms of suspected CAD did not affect all-cause or CV mortality at 10 years.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT01174550<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2025.2882","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:30:58Z","timestamp":1756308658000},"page":"1050","source":"Crossref","is-referenced-by-count":5,"title":["Survival After Initial Stress Testing vs Anatomic Testing in Suspected Coronary Artery Disease"],"prefix":"10.1001","volume":"10","author":[{"given":"Pamela S.","family":"Douglas","sequence":"first","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"},{"name":"Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Stebbins","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borek","family":"Foldyna","sequence":"additional","affiliation":[{"name":"Cardiovascular Imaging Research Center, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manesh R.","family":"Patel","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"},{"name":"Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Mark","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"},{"name":"Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Lu","sequence":"additional","affiliation":[{"name":"Cardiovascular Imaging Research Center, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Cleerly Inc, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svati H.","family":"Shah","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"},{"name":"Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina"},{"name":"Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Martinez","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Alhanti","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Pagidipati","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"},{"name":"Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"22","key":"hbr250011r1","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1161\/CIR.0000000000001029","article-title":"2021 AHA\/ACC\/ASE\/CHEST\/SAEM\/SCCT\/SCMR Guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"144","author":"Gulati","year":"2021","journal-title":"Circulation"},{"issue":"36","key":"hbr250011r2","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes.","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"issue":"14","key":"hbr250011r3","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1056\/NEJMoa1415516","article-title":"Outcomes of anatomical versus functional testing for coronary artery disease.","volume":"372","author":"Douglas","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"hbr250011r4","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa1805971","article-title":"Coronary CT angiography and 5-year risk of myocardial infarction.","volume":"379","author":"Newby","year":"2018","journal-title":"N Engl J Med"},{"issue":"10475","key":"hbr250011r5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S0140-6736(24)02679-5","article-title":"Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland.","volume":"405","author":"Williams","year":"2025","journal-title":"Lancet"},{"issue":"10","key":"hbr250011r6","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003807","article-title":"Changes in medical therapy and lifestyle after anatomical or functional testing for coronary artery disease.","volume":"5","author":"Ladapo","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"hbr250011r7","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.ahj.2014.03.003","article-title":"PROspective Multicenter Imaging Study for Evaluation of chest pain: rationale and design of the PROMISE trial.","volume":"167","author":"Douglas","year":"2014","journal-title":"Am Heart J"},{"issue":"24","key":"hbr250011r8","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1161\/CIRCULATIONAHA.116.024360","article-title":"Prognostic value of noninvasive cardiovascular testing in patients with stable chest pain: insights from the PROMISE trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain).","volume":"135","author":"Hoffmann","year":"2017","journal-title":"Circulation"},{"issue":"3","key":"hbr250011r10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jcct.2019.01.006","article-title":"The SCOT-HEART trial. what we observed and what we learned.","volume":"13","author":"Adamson","year":"2019","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"hbr250011r9","unstructured":"Mini\u00f1o? AM, Klein? RJ. Mortality from major cardiovascular diseases: United States, 2007. US Centers for Disease Control and Prevention. Accessed March 15, 2025. https:\/\/www.cdc.gov\/nchs\/data\/hestat\/cardio2007\/cardio2007.pdf"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2838118\/jamacardiology_douglas_2025_br_250011_1758588916.99152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:02:09Z","timestamp":1759935729000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2838118"}},"subtitle":["Long-Term Follow-Up of the PROMISE Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2025.2882","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}